Relacorilant

N/A

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NameRelacorilant
Drug Alias NameLifyorliCORT-125134
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucocorticoid receptor antagonists
TargetsGlucocorticoid receptor
Therapy Area/IndicationsSolid tumoursCushing SyndromePituitary ACTH Hypersecretion +[14] 
Global Approved IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/03/25
Country/TerritoryBelgiumBulgariaCanada +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCorcept Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of ChicagoCorcept Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCushing SyndromePituitary ACTH HypersecretionProstatic Neoplasms +[10] 
Inactive IndicationsSolid tumoursHepatic InsufficiencyCarcinoma, Pancreatic Ductal +[4] 

Other Information

ATC CodeN/A
Related LinksN/A